Logo image of RADX

RADIOPHARM THERANOSTICS LTD (RADX) Stock Fundamental Analysis

NASDAQ:RADX - Nasdaq - ADR - Currency: USD

4.15  +0.15 (+3.75%)

Fundamental Rating

3

RADX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. RADX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RADX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RADX has reported negative net income.
In the past year RADX has reported a negative cash flow from operations.
RADX Yearly Net Income VS EBIT VS OCF VS FCFRADX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

RADX has a Return On Assets (-45.34%) which is comparable to the rest of the industry.
RADX has a Return On Equity (-78.79%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -45.34%
ROE -78.79%
ROIC N/A
ROA(3y)-49.74%
ROA(5y)N/A
ROE(3y)-98.93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RADX Yearly ROA, ROE, ROICRADX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

RADX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RADX Yearly Profit, Operating, Gross MarginsRADX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

RADX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RADX has been increased compared to 1 year ago.
RADX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RADX Yearly Shares OutstandingRADX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
RADX Yearly Total Debt VS Total AssetsRADX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.94, we must say that RADX is in the distress zone and has some risk of bankruptcy.
RADX has a Altman-Z score of -1.94. This is comparable to the rest of the industry: RADX outperforms 54.95% of its industry peers.
There is no outstanding debt for RADX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.94
ROIC/WACCN/A
WACC10.13%
RADX Yearly LT Debt VS Equity VS FCFRADX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 3.37 indicates that RADX has no problem at all paying its short term obligations.
RADX has a Current ratio of 3.37. This is in the lower half of the industry: RADX underperforms 60.95% of its industry peers.
RADX has a Quick Ratio of 3.37. This indicates that RADX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RADX (3.37) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.37
Quick Ratio 3.37
RADX Yearly Current Assets VS Current LiabilitesRADX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

RADX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.20%, which is quite impressive.
RADX shows a small growth in Revenue. In the last year, the Revenue has grown by 2.33%.
EPS 1Y (TTM)52.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.85%
Revenue 1Y (TTM)2.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RADX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.94% on average per year.
RADX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 342.59% yearly.
EPS Next Y62.17%
EPS Next 2Y-78.51%
EPS Next 3Y-64.86%
EPS Next 5Y19.94%
Revenue Next Year-100%
Revenue Next 2Y1096.32%
Revenue Next 3Y675.81%
Revenue Next 5Y342.59%

3.3 Evolution

RADX Yearly Revenue VS EstimatesRADX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RADX Yearly EPS VS EstimatesRADX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RADX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RADX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RADX Price Earnings VS Forward Price EarningsRADX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RADX Per share dataRADX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A cheap valuation may be justified as RADX's earnings are expected to decrease with -64.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-78.51%
EPS Next 3Y-64.86%

More info and screens

0

5. Dividend

5.1 Amount

RADX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RADIOPHARM THERANOSTICS LTD

NASDAQ:RADX (5/2/2025, 8:19:05 PM)

4.15

+0.15 (+3.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26
Earnings (Next)N/A N/A
Inst Owners16.23%
Inst Owner ChangeN/A
Ins Owners9.33%
Ins Owner ChangeN/A
Market Cap32.29M
Analysts80
Price Target4.44 (6.99%)
Short Float %0.78%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.02
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 9.72
EV/EBITDA N/A
EPS(TTM)-9.68
EYN/A
EPS(NY)-32.49
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0.14
BVpS4.37
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.34%
ROE -78.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.74%
ROA(5y)N/A
ROE(3y)-98.93%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.37
Quick Ratio 3.37
Altman-Z -1.94
F-Score6
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.85%
EPS Next Y62.17%
EPS Next 2Y-78.51%
EPS Next 3Y-64.86%
EPS Next 5Y19.94%
Revenue 1Y (TTM)2.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y1096.32%
Revenue Next 3Y675.81%
Revenue Next 5Y342.59%
EBIT growth 1Y8.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.13%
EBIT Next 3Y-0.65%
EBIT Next 5YN/A
FCF growth 1Y-88.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-95.15%
OCF growth 3YN/A
OCF growth 5YN/A